February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Event Attributes and Opportunities 1,400+ Attendees 768 Companies 158 Company Presentations 2,700+ Partnering Meetings 700 Registered Investors EXPERIENCE the largest, unbiased forum where institutional investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry. HEAR Washington s perspective on policy and other timely developments affecting the industry. EVALUATE fresh investment opportunities including compatible, complementary, and competitive companies. LEARN about the hottest clinical developments and industry catalysts by attending the conference s therapeutic workshops and business roundtables. ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry s leading companies are headed in 2019. GAIN ACCESS to BIO One-on-One Partnering for scouting potential investments and deal partners, optimizing your time at the event. UNIQUE PLATFORM for your company to highlight accomplishments and discuss upcoming milestones. Approximately 190 companies will be chosen based on a selection process evaluating a company s pipeline and R&D activities. GET THE PULSE of the current and proposed investment trends in biotechnology. NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions. bio.org/ceo #BIOCEO19 1
CE February 11-12, 2018 New York Marriott Marquis Audience Demographics Company Type Biotech or pharma, therapeutic R&D 57% Financial, legal, consulting 8% C-LEVEL Other products or services 7% DIRECTOR VP OTHER 64% 11% 12% 13% Public, NPO, Govt., economic development 5% Medical device or technology 4% Investor (buy-side or sell-side research) 4% CMO, CRO 3% Investment bank 2% Academic, tech transfer 2% Other R&D services 2% IT, information 2% Other 4% Company by Region United States 88% Australia, New Zealand 1% Asia 4% Europe 7% Hedge/Mutual Fund (PM, Buyside research 25% Investor Types Sell-side research 14% Family office 13% Investment bank 5% Royalty/debt financing 4% Angel investing 4% Financial Advising 2% Individual investor 2% Other 5% Companies' Primary Therapeutic Area Gynecology and obstetrics 1% Ocular disease 2% Genitourinary disease 3% Genetic disorder 3% Musculoskeletal disease 3% Degeneration 3% Psychiatric disorder 3% Metabolic disorder 4% Dermatological disease 4% Respiratory disease 5% Injury 1% Nutritional disorder 1% All others 5% Neoplasm 13% Neurological disease 9% Inflammatory disease 7% Gastrointestinal disease 6% Endocrine disease 5% Infectious disease 6% Hematological disease 5% Immune disorder 6% Cardiovascular disease 5% Company Size 10 to 50 employees 43% VC/Corporate VC 26% 50 to 200 employees 16% 10,000+ employees 6% 1,000 to 10,000 employees 6% 200 to 1,000 employees 6% <10 employees 23% Event 2 & Event & Sponsorship Prospectus bio.org/ceo #BIOCEO18
February 11-12, 2019 New York Marriott Marquis Fireside Chat Speakers* 2019 Advisory Committee James Antonopoulos, Managing Director, Co-Head of Healthcare Investment Banking, ROTH Capital Partners Deborah Dunsire, MD President and Chief XTuit Pharmaceuticals Jeffrey D. Marrazzo Co-Founder and Chief Spark Therapeutics Lan Huang, PhD Co-Founder, Chairman and Chief Executive Officer, BeyondSpring Pharmaceuticals Vivek Ramaswamy Founder and Chief Roivant Sciences Jie D'Elia, PhD, Executive Director, Business Development Transactions, Bristol-Myers Squibb Jonathan Leff, Partner, Deerfield Management; Chairman, Deerfield Institute Kimberly Nearing, Managing Director, Head of Life Sciences, Cedrus Group; Regional Leader for BayHelix's NY/NJ/PA Chapters Timothy O'Connor, PhD, Executive Vice President, The Rockefeller University Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital Stephen Ritoch, Chairman & Chief Blaise Group International Nassim Usman, PhD, President and Chief Executive Officer, Catalyst Biosciences Vicki Sato, PhD Chairman, Denali Therapeutics; Chairman, Vir Biotechnology Rachel Sherman, MD MPH Principal Deputy Commissioner, U.S. Food and Drug Administration (FDA) *representative list from past CEO conferences bio.org/ceo #BIOCEO19 3
CE February 11-12, 2018 New York Marriott Marquis Sponsorship Opportunities & Benefits Program Sponsorship Number of Registrants Recognition on Conference Website, Materials and Signage Advertisement in Conference Program Access to BIO One-on-One Partnering Partnering Suite and Priority Scheduling of Meetings Guaranteed Speaking Opportunity Program Sponsor 3 Company Presentations Sponsor 3 Networking Opportunities Welcome Reception Sponsor 2 Hospitality Sponsor 2 Closing Reception Sponsor 2 Tabletop Exhibit Sponsor (6 available) 2 Partnering and Social Media BIO One-on-One Partnering System Sponsor 3 Partnering Hospitality Lounge Sponsor 2 Partnering Suite Package 2 Buzz of BIO Contest Sponsor 2 Social Media Sponsor 2 Promotional Opportunities Conference Bag Sponsor 2 Conference Program Sponsor 2 Lanyard Sponsor 2 Digital Daily Sponsor 2 WiFi Sponsor 2 Luggage and Coat Check Sponsor 2 Charging Station Sponsor 1 Hotel Key Card Sponsor 1 Advertising Opportunities Branding Package 0 Conference Program Advertisement 0 Conference Bag Insert 0 High Visibility Signage 0 For more information on sponsorship opportunities, please contact: Melissa Arndorfer: marndorfer@bio.org 202-962-9512 Event 4 & Event & Sponsorship Prospectus bio.org/ceo #BIOCEO18
February 11-12, 2019 New York Marriott Marquis 2018 Sponsors Double Helix Sponsors Helix Sponsor Supporting Bank Sponsors Conference Sponsors N E W Y O R K C I T Y Regional Co-Host bio.org/ceo #BIOCEO19 5